News Release

Obesity as a risk factor for colorectal cancer underestimated so far

Weight loss before diagnosis obscures correlation

Peer-Reviewed Publication

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Obesity is a known risk factor for colorectal cancer. Scientists at the German Cancer Research Center (DKFZ) have now shown that this association has probably been significantly underestimated so far. The reason: many people unintentionally lose weight in the years before a colorectal cancer diagnosis. If studies only consider body weight at the time of diagnosis, this obscures the actual relationship between obesity and colorectal cancer risk. In addition, the current study shows that unintentional weight loss may be an early indicator of colorectal cancer.

Obesity is a risk factor for a whole range of cancers. This association is particularly clear, for example, in the case of endometrial cancer, kidney cancer and also colorectal cancer. According to previous estimates, obese people have a risk of developing colorectal cancer that is about one-third higher than that of normal weight individuals.

"However, these studies have so far not taken into account that many affected people lose weight in the years before their colorectal cancer diagnosis," says Hermann Brenner, epidemiologist and prevention expert at the German Cancer Research Center. "This has led to the risk contribution of obesity being significantly underestimated in many trials."

To assess the magnitude of this bias, Brenner's researchers evaluated data from the DACHS study*. The nearly 12,000 study participants included in the current evaluation had provided information on their body weight at the time of diagnosis and had also reported their weight in the years preceding diagnosis (measured at 10-year intervals).

On the basis of body weight at the time of diagnosis, no indication of a relationship between body weight and colorectal cancer risk could be established. The picture was quite different, however, when the researchers looked at the participants' earlier body weight: Here, a strong correlation between overweight and the probability of developing colorectal cancer was found, which was most pronounced 8 to 10 years before diagnosis. Study participants who were highly overweight - referred to as obese** - during this period were twice as likely as those of normal weight to develop colorectal cancer. "If we had only looked at weight at baseline, as has been done in many previous studies, we would have completely missed the link between obesity and increased risk of colorectal cancer," said Marko Mandic, the study's first author.

In their analyses, Brenner's team was able to identify another trend: A striking number of the study participants affected by colorectal cancer had unintentionally lost weight before diagnosis. An unintentional weight loss of two kilos or more within two years prior to diagnosis (or study entry) occurred 7.5 times more frequently in cancer-affected individuals than in those in the control group. "During this period, the cancer is already there, but not yet noticeable by symptoms. Doctors should therefore regularly ask their patients about unintentional weight loss," Brenner appeals, adding, "Unintentional weight loss could also be an early indication of other cancers or other diseases and should be carefully clarified."


Marko Mandic; Fatemeh Safizadeh; Tobias Niedermaier; Michael Hoffmeister, Hermann Brenner: Association of Overweight, Obesity, and Recent Weight Loss With Colorectal Cancer Risk.

JAMA Network Open. 2023, doi:10.1001/jamanetworkopen.2023.9556


* DACHS stands for: "Colorectal Cancer: Opportunities for Prevention through Screening" and is one of the world's largest case-control studies of colorectal cancer, which it has conducted at the German Cancer Research Center since 2003. Between 2003 and 2020, a total of 6,602 colorectal cancer sufferers and 7,950 people without colorectal cancer participated.


** Overweight above a body mass index of ≥30 kg/m2 is considered obesity.



The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.